<DOC>
	<DOCNO>NCT01465919</DOCNO>
	<brief_summary>The purpose study evaluate anti-depressive efficacy mirtazapine depression induce peginterferon alpha-2a ribavirin treatment Korean patient chronic hepatitis C .</brief_summary>
	<brief_title>Efficacy Study Mirtazapine Treat Interferon-related Depression During Antiviral Therapy Hepatitis C</brief_title>
	<detailed_description>Depression common serious adverse event ( 30 % -50 % ) interferon treatment chronic hepatitis C. Adequate control depressive symptom might enable adhere antiviral therapy lead favorable prognosis patient chronic hepatitis C. Mirtazapine effective antidepressant depressive mood well insomnia anxiety . Mirtazapine also relatively low drug-drug interaction , important patient hepatic dysfunction . In study , investigator go perform 8-week , randomize , open label trial compare anti-depressive efficacy mirtazapine supportive psychotherapy depression induce peginterferon alpha-2a ribavirin treatment Korean patient chronic hepatitis C .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Major depressive episode diagnose Diagnostic Statistical Manual Diploma Social MedicineIV ( DSMIV ) Hamilton Depression Scale ( HAMD17 ) â‰¥ 14 Any axis I primary diagnosis except major depressive disorder Having serious adverse event hypersensitivity mirtazapine Having major depressive disorder prior first injection interferon</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>interferon</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>mirtazapine</keyword>
</DOC>